Dear Colleagues, 

More than 900,000 patients were diagnosed with primary liver cancers worldwide in 2020. Furthermore, at least 40% of patients with colorectal cancers will develop liver-only metastases, and various percentages of patients with other primary malignancies develop liver metastases. Although the treatment modalities for patients with primary or secondary hepatic malignancies evolved over the last three decades, death rates remain high. In 2020, more than 830,000 patients with primary liver cancer and 935,000 with colorectal cancer, of whom more than 70% had liver metastases, died worldwide in 2020.

Renewed efforts are made to detect liver malignancies in early stages, increase the number of patients who can underwent a curative treatment, develop new efficient therapeutic strategies, identify new therapeutic targets, and personalize therapy according to the molecular profile of the tumors.

We invite surgeons, gastroenterologists, oncologists, radiologists, pathologists, and researchers around the world to report their results in fields centered around diagnoses, treatment, and basic science research in relation to this topic.

Clinical series reporting on diagnostic and therapeutic methods, surgical strategies (e.g., methods for conversion to respectability of initially unresectable liver tumors, liver transplantation, etc.), the impact of antiviral medications on the incidence of liver cancers, results of the new oncologic therapies on the long-term outcome of these patients, as well as specific anesthesia and the ICU management of patients with liver tumors are welcomed for this collection. We also invite colleagues involved in the field of molecular, genetic, or epigenetic research related to liver malignancies and report their results in this Special Issue. Comprehensive reviews and meta-analyses on liver malignancies are also welcomed, as well as special case reports that could open the door toward new therapeutic approaches addressed to such patients.

Dr. Sorin Tiberiu Alexandrescu
Dr. Narcis Octavian Zarnescu
Dr. Adina Emilia Croitoru
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocellular carcinoma
• cholangiocarcinoma
• liver cirrhosis
• liver metastases
• hepatic and extrahepatic metastases
• molecular profile
• liver surgery
• liver transplantation
• immunotherapy
• ICU management